ALBANY, N.Y., Nov. 17, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announces that it has received a letter from the United Stated Food and Drug Administration (FDA) closing out the warning letter it received from the FDA in January 2011 regarding certain promotional activities related to the NanoKnife System.
“Over the past four years we have worked diligently to improve our quality and compliance systems, including product design, manufacturing and marketing. I am very proud of our team’s progress and this milestone is further evidence of our ongoing commitment to quality and compliance,” said Joseph M. DeVivo, President and CEO of AngioDynamics. “Closing out the January 2011 Warning Letter related to NanoKnife marketing activities is another positive step in our commercialization of NanoKnife. Along with the Certificates to Foreign Governments that we attained at all our facilities earlier this year, we look to maintain our high quality standards as we build our business worldwide.”
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics, the AngioDynamics logo and NanoKnife are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
Company Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 email@example.com Investor Relations Contacts: EVC Group, Inc. Doug Sherk/Chris Dailey (646) 445-4801 firstname.lastname@example.org/ email@example.com Media Contact: EVC Group, Inc. Dave Schemelia (646) 201-5431 firstname.lastname@example.org